Vascular neuropeptide Y contributes to atherosclerotic plaque progression and perivascular mast cell activation

Atherosclerosis

Volumn 235, Issue 1, 2014, Pages 196-203

  Lagraauw, H Maxime ^a   Westra, Marijke M ^a   Bot, Martine ^a   Wezel, Anouk ^a   Van Santbrink, Peter J ^a   Pasterkamp, Gerard ^b   Biessen, Erik A L ^c   Kuiper, Johan ^a   Bot, Ilze ^a,d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Lentivirus; Mast cell; Nerve fiber; Neuropeptide Y

Indexed keywords

APOLIPOPROTEIN E; BETA N ACETYLHEXOSAMINIDASE; CHYMASE; COMPOUND 48-80; INTERLEUKIN 6; LENTIVIRUS VECTOR; NEUROPEPTIDE Y; TRYPTASE;

ANIMAL EXPERIMENT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CELL ACTIVATION; CELL FUNCTION; CONTROLLED STUDY; DISEASE COURSE; ENDARTERECTOMY; FAT CONTENT; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MAST CELL; MEDIATOR RELEASE; MOUSE; NONHUMAN; PERIVASCULAR MAST CELL ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ISOLATION; VASCULAR SMOOTH MUSCLE; ANIMAL; ATHEROSCLEROSIS; BLOOD; CYTOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; INFLAMMATION; KNOCKOUT MOUSE; LENTIVIRINAE; METABOLISM; PATHOLOGY;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERLEUKIN-6; LENTIVIRUS; MAST CELLS; MICE; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; NEUROPEPTIDE Y; PLAQUE, ATHEROSCLEROTIC; TRYPTASES;

EID: 84901856694     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.04.025     Document Type: Article

References (45)

1. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
2. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. NEngl J Med 2005, 352:1685-1695.
3. Laine P., Naukkarinen A., Heikkilä L., Penttilä A., Kovanen P.T. Adventitial mast cells connect with sensory nerve fibers in atherosclerotic coronary arteries. Circulation 2000, 101:1665-1669.
4. Bot I., Jager S.C.A.de, Bot M., van Heiningen S.H., de Groot P., Veldhuizen R.W., et al. Short communication: the neuropeptide substance P mediates adventitial mast cell activation and induces intraplaque hemorrhage in advanced atherosclerosis. Circ Res 2010, 106:89-92.
5. Longhurst J.C. Coronary arteriolar vasoconstriction in myocardial ischaemia: reflexes, sympathetic nervous system, catecholamines. Eur Heart J 1990, 11:43-52.
6. Li L., Lee E.W., Ji H., Zukowska Z. Neuropeptide Y-induced acceleration of postangioplasty occlusion of rat carotid artery. Arterioscler Thromb Vasc Biol 2003, 23:1204-1210.
7. Zukowska-Grojec Z., Karwatowska-Prokopczuk E., Fisher T.A., Ji H. Mechanisms of vascular growth-promoting effects of neuropeptide Y: role of its inducible receptors. Regul Pept 1998, 75-76:231-238.
8. Ekstrand A.J., Cao R., Björndahl M., Nyström S., Jönsson-Rylander A.-C., Hassani H., et al. Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci 2003, 100:6033-6038.
9. Kuo L.E., Kitlinska J.B., Tilan J.U., Li L., Baker S.B., Johnson M.D., et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007, 13:803-811.
10. Hirsch D., Zukowska Z. NPY and stress 30 years later: the peripheral view. Cell Mol Neurobiol 2012, 32:645-659.
11. Dimitrijević M., Stanojević S. The intriguing mission of neuropeptide Y in the immune system. Amino Acids 2013, 45:41-53.
12. Wheway J., Mackay C.R., Newton R.A., Sainsbury A., Boey D., Herzog H., et al. Afundamental bimodal role for neuropeptide Y1 receptor in the immune system. JExp Med 2005, 202:1527-1538.
13. Shah S.H., Freedman N.J., Zhang L., Crosslin D.R., Stone D.H., Haynes C., et al. Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. PLoS Genet 2009, 5:e1000318.
14. Karvonen M.K., Valkonen V.-P., Lakka T.A., Salonen R., Koulu M., Pesonen U., et al. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 2001, 159:145-151.
15. Koulu M., Movafagh S., Tuohimaa J., Jaakkola U., Kallio J., Pesonen U., et al. Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization. Ann Med 2004, 36:232-240.
16. Pankajakshan D., Jia G., Pipinos I., Tyndall S.H., Agrawal D.K. Neuropeptide Y receptors in carotid plaques of symptomatic and asymptomatic patients: effect of inflammatory cytokines. Exp Mol Pathol 2011, 90:280-286.
17. von der Thüsen J.H., van Berkel T.J.C., Biessen E.A.L. Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation 2001, 103:1164-1170.
18. -/- mice. Cardiovasc Res 2011, 89:244-252.
19. Hoen P.A.C.'t, der Lans C.A.C.V., Eck M.V., Bijsterbosch M.K., Berkel T.J.C.V., Twisk J. Aorta of ApoE-deficient mice responds to atherogenic stimuli by a prelesional increase and subsequent decrease in the expression of Antioxidant enzymes. Circ Res 2003, 93:262-269.
20. Verhoeven B.A.N., Velema E., Schoneveld A.H., de Vries J.P.P.M., de Bruin P., Seldenrijk C.A., et al. Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design. Eur J Epidemiol 2004, 19:1127-1133.
21. Davies M.J., Richardson P.D., Woolf N., Katz D.R., Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993, 69:377-381.
22. Falk E., Shah P.K., Fuster V. Coronary plaque Disruption. Circulation 1995, 92:657-671.
23. van der Wal A.C., Becker A.E., van der Loos C.M., Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994, 89:36-44.
24. Zufferey R., Nagy D., Mandel R.J., Naldini L., Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery invivo. Nat Biotechnol 1997, 15:871-875.
25. Sastry L., Johnson T., Hobson M.J., Smucker B., Cornetta K. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther 2002, 9:1155-1162.
26. Bot I., Guo J., Eck M.V., Santbrink P.J.V., Groot P.H.E., Hildebrand R.B., et al. Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown of CCR2 function invivo. Blood 2005, 106:1147-1153.
27. Seppen J., Rijnberg M., Cooreman M.P., Oude Elferink R.P.J. Lentiviral vectors for efficient transduction of isolated primary quiescent hepatocytes. JHepatol 2002, 36:459-465.
28. Bot I., von der Thüsen J.H., Donners M.M.P.C., Lucas A., Fekkes M.L., de Jager S.C.A., et al. Serine protease inhibitor serp-1 strongly impairs atherosclerotic lesion formation and induces a stable plaque phenotype in ApoE-/- mice. Circ Res 2003, 93:464-471.
29. Bot I., de Jager S.C.A., Zernecke A., Lindstedt K.A., van Berkel T.J.C., Weber C., et al. Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice. Circulation 2007, 115:2516-2525.
30. HPM van der Kleij, Ma D., Redegeld F.A.M., Kraneveld A.D., Nijkamp F.P., Bienenstock J. Functional expression of neurokinin 1 receptors on mast cells induced by IL-4 and stem cell factor. JImmunol 2003, 171:2074-2079.
31. Straub R.H., Mayer M., Kreutz M., Leeb S., Schölmerich J., Falk W. Neurotransmitters of the sympathetic nerve terminal are powerful chemoattractants for monocytes. JLeukoc Biol 2000, 67:553-558.
32. Sun J., Sukhova G.K., Wolters P.J., Yang M., Kitamoto S., Libby P., et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 2007, 13:719-724.
33. Li L., Najafi A.H., Kitlinska J.B., Neville R., Laredo J., Epstein S.E., et al. Of mice and men: neuropeptide Y and its receptors are associated with atherosclerotic lesion burden and vulnerability. JCardiovasc Transl Res 2011, 4:351-362.
34. Ruohonen S.T., Abe K., Kero M., Toukola L., Ruohonen S., Röyttä M., et al. Sympathetic nervous system-targeted neuropeptide Y overexpression in mice enhances neointimal formation in response to vascular injury. Peptides 2009, 30:715-720.
35. Dekker R.J., van Thienen J.V., Rohlena J., de Jager S.C., Elderkamp Y.W., Seppen J., et al. Endothelial KLF2 links local arterial shear stress levels to the expression of vascular tone-regulating genes. Am J Pathol 2005, 167:609-618.
36. Bot M., de Jager S.C.A., MacAleese L., Lagraauw H.M., van Berkel T.J.C., Quax P.H.A., et al. Lysophosphatidic acid triggers mast cell-driven atherosclerotic plaque destabilization by increasing vascular inflammation. JLipid Res 2013, 54:1265-1274.
37. Ya-ling Tang Y.Y. Mast cell degranulator compound 48-80 promotes atherosclerotic plaque in apolipoprotein E knockout mice with perivascular common carotid collar placement. Chin Med J Engl 2009, 122:319-325.
38. Willems S., Vink A., Bot I., Quax P.H.A., de Borst G.J., de Vries J.-P.P.M., et al. Mast cells in human carotid atherosclerotic plaques are associated with intraplaque microvessel density and the occurrence of future cardiovascular events. Eur Heart J 2013, 34:3699-3706.
39. Cross L.J., Beck-Sickinger A.G., Bienert M., Gaida W., Jung G., Krause E., et al. Structure activity studies of mast cell activation and hypotension induced by neuropeptide Y (NPY), centrally truncated and C-terminal NPY analogues. Br J Pharmacol 1996, 117:325-332.
40. Emadi-Khiav B., Mousli M., Bronner C., Landry Y. Human and rat cutaneous mast cells: involvement of a G protein in the response to peptidergic stimuli. Eur J Pharmacol 1995, 272:97-102.
41. Shen G.H., Grundemar L., Zukowska-Grojec Z., Håkanson R., Wahlestedt C. C-terminal neuropeptide Y fragments are mast cell-dependent vasodepressor agents. Eur J Pharmacol 1991, 204:249-256.
42. Ferry X., Brehin S., Kamel R., Landry Y. Gprotein-dependent activation of mast cell by peptides and basic secretagogues. Peptides 2002, 23:1507-1515.
43. Jaakkola U., Kakko T., Juonala M., Lehtimäki T., Viikari J., Jääskeläinen A.E., et al. Neuropeptide Y polymorphism increases the risk for asthma in overweight subjects; protection from atherosclerosis in asthmatic subjects - the cardiovascular risk in young Finns study. Neuropeptides 2012, 46:321-328.
44. Najafi A.H., Aghili N., Tilan J.U., Andrews J.A., Peng X., Lassance-Soares R.M., et al. Anew murine model of stress-induced complex atherosclerotic lesions. Dis Model Mech 2013, 6:323-331.
45. den W.K., Tempel D., Bot I., Biessen E.A., Joosten L.A., Netea M.G., et al. Mast cells induce vascular smooth muscle cell apoptosis via a toll-like receptor 4 activation pathway. Arterioscler Thromb Vasc Biol 2012, 32:1960-1969.